BVXV:NSD-BiondVax Pharmaceuticals Ltd (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.12

Change

+0.04 (+1.30)%

Market Cap

USD 0.04B

Volume

0.05M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and related illnesses in Israel. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Company Website : http://www.biondvax.com

Address : Jerusalem BioPark Building, Jerusalem, Israel, 7414002

Employees : 21

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 2.26

52 Week High : 62.00

Short Ratio : 5.28

52 Week Low : 2.35

Shorted Shares : 431,865

200 Day Moving Average : 3.71

Shorted Shares Previous Month : 484,004

50 Day Moving Average : 2.99

Shares Held By Insiders : 298.21%

Short Percentage : 3.00%

Shares Held by Institutions : 2.04%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-3.28 (-1.62%)

 USD81.30B 135.70 104.16
REGN Regeneron Pharmaceuticals, Inc

+1.91 (+0.36%)

 USD57.11B 15.26 11.77
BNTX BioNTech SE

-1.78 (-0.83%)

 USD49.23B -99,999.99 35.63
VRTX Vertex Pharmaceuticals Incorpo..

-0.51 (-0.27%)

 USD48.76B 17.95 12.38
ALXN Alexion Pharmaceuticals, Inc

+0.72 (+0.40%)

 USD39.91B 58.41 42.10
BGNE BeiGene, Ltd

-7.33 (-2.23%)

 USD30.29B N/A N/A
GMAB Genmab A/S

-0.61 (-1.40%)

 USD29.17B 26.59 3.71
SGEN Seagen Inc

+2.93 (+1.91%)

 USD27.46B 42.22 39.29
RPRX Royalty Pharma plc

-0.11 (-0.25%)

 USD26.79B 22.60 15.62
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing BVXV

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.03% 65% D 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.03% 65% D 55% F
Trailing 12 Months  
Capital Gain -86.95% 1% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -86.95% 1% F 1% F
Trailing 5 Years  
Capital Gain -17.75% 44% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.75% 44% F 18% F
Average Annual (5 Year Horizon)  
Capital Gain 61.43% 81% B- 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 61.43% 81% B- 89% B+
Risk Return Profile  
Volatility (Standard Deviation) 161.57% 13% F 8% F
Risk Adjusted Return 38.02% 63% D 57% F
Market Capitalization 0.04B 5% F 9% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 11.71 14% F 12% F
Price / Cash Flow Ratio -0.61 11% F 59% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 14.03% 90% A- 84% B
Return on Assets 5.31% 94% A 83% B
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.28 49% F 30% F
Short Percent 3.83% 74% C 46% F
Beta 2.26 12% F 9% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.